Prevision Policy (@PrevisionPolicy) header
Prevision Policy (@PrevisionPolicy) profile picture

Breaking analysis for biopharma

Washington, DC
Joined February 2010
Early #Alzheimer's Disease revised draft guidance https://nitter.gq/t.co/m9A8DmpKKs
#Epilepsy: Partial onset seizures draft guidance https://nitter.gq/t.co/QpMjfNcbKx
Duchenne Muscular Dystrophy final guidance https://nitter.gq/t.co/mC1ajZ57qN
Draft Amyotrophic Lateral Sclerosis guidance https://nitter.gq/t.co/CCbXcwqubr
#Migraine: Developing drugs for acute treatment https://nitter.gq/t.co/CjiRO4keHo
Akcea’s Volanesoren AdComm May 10
Pre-Request for Designation final guidance https://nitter.gq/t.co/ICMWzifQUQ
ICER Spark’s Luxturna #GeneTherapy report https://nitter.gq/t.co/wCk7MUJfJH
.@Amgen’s Blincyto sBLA to Oncologic Drugs AdComm March 7
Regulatory classification of #pharmaceutical co-crystals guidance https://nitter.gq/t.co/W5NypeFrcZ
Exparel Ad Comm briefing docs https://nitter.gq/t.co/kNiuddNKun
Hydexor Ad Comm briefing docs https://nitter.gq/t.co/qL3AXNjyLD
#CBER's Vaccines and Related Biological Products AdComm March 1
Prevision Policy retweeted
This month’s #340BConf will feature the seasoned pro Michael McCaughan @RPMReportMike of @PrevisionPolicy on what to expect in year two of the Trump era.
.@US_FDA's Office of Generic Drugs 2017 report https://nitter.gq/t.co/mZlrLiVMtc
.@GileadSciences’ triple combo #HIV treatment Biktarvy gets FDA approval #PvPClips
Product-Specific Bioequivalence ANDA Guidances https://nitter.gq/t.co/8k9Hpp68n8
.@ExpressScripts #drugspending report released https://nitter.gq/t.co/0XJLpGHLu2
New CBER-CDER Data Standards Strategy https://nitter.gq/t.co/0ZYqhEOpDj